Perigard 2mg Tablet 10s

Side Effects of Perigard 2mg Tablet 10s

Renal dysfunction, pancreatitis, blood disorders (e.g. agranulocytosis, neutropenia, thrombocytopenia). Cough, dizziness, vertigo, hypotension, headache, asthenia, back pain, sinusitis, chest pain, abnormal ECG, sleep disorders, viral infection, upper extremity pain, hypertonia, fever, proteinuria, ear infection, palpitation, GI disorders (e.g. nausea, dyspepsia, abdominal pain), rash. Potentially Fatal: Angioedema and severe anaphylactic reactions. Rarely, hepatic necrosis.

Drug Interactions

May enhance hypotensive effect w/ diuretics. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. ciclosporin, heparin, indometacin). May increase serum levels and toxicity of lithium. Antihypertensive effect may be reduced by aspirin or other NSAIDs. Coadministration w/ NSAIDs may also increase the risk of renal impairment. Increased risk of hypoglycaemia w/ antidiabetic agents. Rarely, nitritoid reactions occur w/ concomitant use of gold (sodium aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function (including acute renal failure) w/ aliskiren in patients w/ diabetes or renal impairment.

Contraindications

History of angioedema related to previous ACE inhibitor treatment; hereditary or idiopathic angioedema. Concomitant use w/ aliskiren in patients w/ diabetes or renal impairmenrt. Pregnancy.

Mechanism of Action

Perindopril competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This produces hypotensive effect and beneficial effect in CHF. Onset: 1-2 hr. Absorption: Rapidly absorbed from the GI tract. Bioavailability: Perindopril (75%); perindoprilat (approx 25%). Time to peak plasma concentration: 3-4 hr (perindoprilat). Distribution: Plasma protein binding: 60% (perindopril); 10-20% (perindoprilat). Metabolism: Hepatically hydrolysed to perindoprilat (active metabolite) and inactive metabolites including glucuronides. Excretion: Mainly via urine (as unchanged drug, as metabolites). Elimination half-life (active metabolite): 25-30 hr or longer; excretion reduced in renal impairment. Both drug and active metabolite are dialysable.

Special Precautions

Patients w/ history of angioedema unrelated to ACE inhibitor treatment. Risk factors for hyperkalaemia. Collagen vascular disease. Unstented unilateral/bilateral renal artery stenosis; aortic stenosis. Patients undergoing surgery or during anaesthesia. Renal and hepatic impairment. Lactation. Patient Counseling May impair ability to drive or operate machinery. Monitoring Parameters Correct volume and/or salt depletion prior to treatment. Monitor BP, serum electrolytes and creatinine levels frequently.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.